A. Fasolo

C. Sessa, A. Fasolo, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

PD-1 Blockade in Anaplastic Thyroid Carcinoma

P. Ascierto, R. Ramlau, A. Santoro, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist.

A. Fasolo, L. Gianni, M. Broggini, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours

A. Fasolo, Juanita Lopez, A. Dowlati, 2020, British Journal of Cancer.

Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer

A. Fasolo, L. Gianni, G. Mariani, 2009, Nature Clinical Practice Oncology.

A comparison of behavioural change in Drosophila during exposure to thermal stress

A. Fasolo, R. A. Krebs, 2004 .

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

M. Kudo, J. Bruix, A. Zhu, 2022, Journal of Experimental & Clinical Cancer Research.

Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.

A. Mancuso, C. Sessa, A. Fasolo, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

C. Sessa, A. Fasolo, S. Cresta, 2015, British journal of clinical pharmacology.

67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

P. Sunpaweravong, J. Furuse, G. Abou-Alfa, 2022, Annals of Oncology.

714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

P. Sunpaweravong, J. Furuse, G. Abou-Alfa, 2022, Annals of Oncology.

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

E. Raymond, A. Fasolo, E. Assenat, 2021, British Journal of Cancer.

PD-020Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib

E. Raymond, A. Fasolo, S. Faivre, 2016 .

Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma

C. Sessa, A. Fasolo, L. Gianni, 2008 .

An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors.

C. Sessa, S. Marsoni, A. Fasolo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.

P. Ascierto, R. Ramlau, L. Paz-Ares, 2018 .

Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours

K. Papadopoulos, A. Fasolo, A. Naing, 2019, Annals of Oncology.

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Y. Qi, C. Sotiriou, B. Haibe-Kains, 2013, Breast Cancer Research.

Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in patients (pts) with heavily pretreated HER2-positive metastatic breast cancer (MBC): Pooled data of extension cohorts of phase Ib/II studies.

F. André, A. Fasolo, L. Gianni, 2010 .

Maintenance With Everolimus (RAD001) and Trastuzumab After Discontinuation of Chemotherapy in Heavily Pretreated HER-2+Metastatic Breast Cancer Patients: Pooled Data of Extension Cohorts of Phase Ib/II Studies

F. André, A. Fasolo, L. Gianni, 2010 .

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

D. Jäger, H. Wakelee, S. Ou, 2016 .

Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

J. Bergh, F. Cardoso, A. Fasolo, 2008 .

RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG)

P. Wen, M. Campone, A. Boran, 2018, Neuro-Oncology.

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib.

A. Fasolo, E. Assenat, S. Faivre, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab.

J. Bergh, F. Cardoso, A. Fasolo, 2009 .

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

J. Blay, P. Wen, M. Campone, 2021, Clinical Trials.